This section will provide online tools and resource guides to help our patients better understand the issues and complexities surrounding today's treatment modalities.

See Dr. Simon's interview about new treatments for decreased sexual desire on "Let's Talk Live" - News Channel 8.

New! July 19, 2010 - Dr. Simon makes his second appearance on "Let's Talk Live" to discuss a segment called, "Get Back Your Sexual Desires".

To view this video, click on the image below:

Take a look at a recent Washington Post article on sexual desire. This article, written by Daphne Miller, quotes Dr. Simon on the subject of sexual function, but all other information is not endorsed by James A Simon, MD, PC.

Click here to see the article.

"Female sexual dysfunctions (FSDs) are considered common and can have a negative impact on the emotional and psychological well-being of the patient as well as the patient’s relationship with her partner.1,2 Despite a lack of consensus regarding various models of female sexual response, researchers have gained a better understanding of the physiologic underpinnings of these conditions.
In this presentation, I will review the classification and pathophysiology of FSDs. I will also review what is currently known about the prevalence of reported sexual problems, of which decreased desire is the most common." Click here to view Dr. Simon's presentation on Female Sexual Dysfunctions.

Handling those Hot Flashes this Holiday Season:

Take a listen to Dr. Simon’s “appearance” on HealthRadio, an online source for health advice. This informative webcast provides information valuable for menopausal issues during the holiday season and year-round. Click here to view the webcast.

The Menopause Book List:

Dr. Simon’s Picks for Up-To-Date Menopause Reading

Click here for "The Menopause Book List"

 Information for YAZ^®, YASMIN^®, and Ocella^TM 

Recent television advertisements have caused concern amongst users of YAZ^®, YASMIN^®, and Ocella^TM. For more information on these advertisements and the safety of this group of oral contraceptives, see our online pamphlet “YAZ^®, YASMIN^®, and Ocella^TM”.

Click here to read "YAZ^®, YASMIN^®, and Ocella^TM" (PDF Document - 88Kb)

Information for ESTRATEST^® users 

If you’ve been using ESTRATEST^® or ESTRATEST^® HS for the treatment of menopausal symptoms or sexual interest, it might have come as a surprise to you that both drugs have now been removed from the market.

Please see our online pamphlet, "What Happened to ESTRATEST^®?" for more information regarding these drugs and their removal from the pharmaceutical market.

  Click here to read "What Happened to ESTRATEST^®?" (PDF Document - 170Kb)

 Information for Users of Bisphosphonates [Fosamax^® (Alendronate), Actonel^® (Risedronate), Boniva^® (Ibandronate)]

On-going media coverage regarding bisphosphonates (a class of drugs used to treat osteoporosis) may have some users confused as to the risks and benefits of these drugs.

Please see our online pamphlet “Bisphosphonates and ONJ: Risks, Benefits, and Prevention” for more information.

Click here to read "Bisphosphonates and ONJ: Risks, Benefits, and Prevention" (PDF - 32 Kb) 

FRAX - WHO Fracture Risk Assessment Tool

The FRAX® tool has been developed by the World Health Organization (WHO) to evaluate fracture risk of patients.  It is based on individual patient models that integrate the risks associated with clinical risk factors as well as bone mineral denisty (BMD) at the femoral neck.

Click here to access the WHO Fracture Risk Assessment Tool.